April 2016April 2016
New Product - Opdivo
Opdivo (nivolumab) is a fully human IgG4 monoclonal antibody which binds to programmed death-1 (PD-1) receptor and blocks its interaction with ligands PD L1 and PD L2, potentiating T cell responses including antitumour responses. Opdivo as monotherapy is indicated for the treatment of unresectable (stage III) or metastatic (stage IV) melanoma. Opdivo in combination with Yervoy (ipilimumab) is indicated for the treatment of metastatic (stage IV) melanoma with M1c disease or elevated lactic dehydrogenase. Opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) with progression on or after prior chemotherapy. Opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic nonsquamous NSCLC with progression on or after prior chemotherapy. In patients with tumour EGFR or ALK genomic aberrations, Opdivo should be used after progression on or after targeted therapy. Opdivo concentrate solution for infusion is available as 40 mg/4 mL and 100 mg/10 mL in vials of 1’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au